What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acromegaly (2 trials)
- Main trialPhase 2
- “Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly”In the company’s words, NCT07641179 on ClinicalTrials.gov
Other drugs for Acromegaly
- NTQ6179Nanjing Chia-tai Tianqing Pharmaceutical · Phase 1
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2027 | A Study to Evaluate MAR002 for Acromegaly | |
| Phase 1Recruiting | Jul 2026 | Study of MAR002 in Healthy Men |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026